ZA9711317B - Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them. - Google Patents

Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them.

Info

Publication number
ZA9711317B
ZA9711317B ZA9711317A ZA9711317A ZA9711317B ZA 9711317 B ZA9711317 B ZA 9711317B ZA 9711317 A ZA9711317 A ZA 9711317A ZA 9711317 A ZA9711317 A ZA 9711317A ZA 9711317 B ZA9711317 B ZA 9711317B
Authority
ZA
South Africa
Prior art keywords
compositions
processes
preparation
purine derivatives
substituted purine
Prior art date
Application number
ZA9711317A
Other languages
English (en)
Inventor
Anuschriwan Payman
Jochen Knolle
Volkmar Wehner
Gerhard Breiphol
Jean-Francois Gourvest
Denis Carniato
Thomas Richard Gadek
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of ZA9711317B publication Critical patent/ZA9711317B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9711317A 1996-12-20 1997-12-17 Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them. ZA9711317B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653646A DE19653646A1 (de) 1996-12-20 1996-12-20 Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung

Publications (1)

Publication Number Publication Date
ZA9711317B true ZA9711317B (en) 1998-06-22

Family

ID=7815761

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9711317A ZA9711317B (en) 1996-12-20 1997-12-17 Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them.

Country Status (22)

Country Link
EP (1) EP0853084B1 (hu)
JP (1) JP4620190B2 (hu)
KR (1) KR19980064655A (hu)
CN (2) CN1101816C (hu)
AR (1) AR010700A1 (hu)
AT (1) ATE404562T1 (hu)
AU (1) AU728865B2 (hu)
BR (1) BR9706387A (hu)
CA (1) CA2225366C (hu)
CZ (1) CZ294437B6 (hu)
DE (2) DE19653646A1 (hu)
HK (1) HK1012190A1 (hu)
HU (1) HUP9702507A3 (hu)
ID (1) ID19254A (hu)
IL (1) IL122642A0 (hu)
NO (1) NO314583B1 (hu)
NZ (1) NZ329431A (hu)
PL (1) PL323969A1 (hu)
RU (1) RU2228335C2 (hu)
TR (1) TR199701647A2 (hu)
TW (1) TW523515B (hu)
ZA (1) ZA9711317B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1140511C (zh) 1998-04-09 2004-03-03 明治制果株式会社 作为整合素αvβ3拮抗剂的氨基哌啶衍生物
AU2713500A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1065208A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
WO2001010844A1 (en) 1999-08-05 2001-02-15 Meiji Seika Kaisha, Ltd. φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM
EP1176145A1 (en) * 2000-07-28 2002-01-30 Aventis Pharma Deutschland GmbH Novel guanidino derivatives as inhibitors of cell adhesion
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
KR100438820B1 (ko) * 2001-03-05 2004-07-05 삼성코닝 주식회사 Ιιι-ⅴ족 화합물 반도체 기판의 제조 방법
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
PT2101805E (pt) 2007-01-18 2013-01-31 Merck Patent Gmbh Terapia específica e medicamento usando ligandos integrina para tratar o cancro
SI2206727T1 (sl) 2007-10-11 2015-06-30 Daiichi Sankyo Company, Limited Protitelo, ki cilja osteoklast - soroden protein Siglec-15
NZ586129A (en) * 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
MX343049B (es) 2009-04-09 2016-10-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
RU2013119983A (ru) 2010-10-05 2014-11-20 Дайити Санкио Компани, Лимитед Антитело, направленное на связанный с остеокластами белок сиглек-15
KR20150003170A (ko) 2012-03-30 2015-01-08 다이이찌 산쿄 가부시키가이샤 ＣＤＲ 개변 항 Ｓｉｇｌｅｃ-15 항체
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4730696Y1 (hu) * 1966-12-10 1972-09-13
JPS6396663A (ja) * 1986-10-13 1988-04-27 Mita Ind Co Ltd 静電荷像現像用トナ−
JPS6396553A (ja) * 1986-10-14 1988-04-27 Sekisui Chem Co Ltd 充填剤
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
MX9207334A (es) * 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
FR2700337B1 (fr) * 1993-01-11 1995-04-14 Lafon Labor Dérivés d'imidazopyridine-2-one, leur procédé de préparation et leur utilisation en thérapeutique.
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US6110923A (en) * 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
BR9508178A (pt) * 1994-06-29 1997-11-18 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
WO1996020212A2 (en) * 1994-12-28 1996-07-04 Buchardt, Dorte Peptide nucleic acid incorporating a chiral backbone
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
JP2001518054A (ja) * 1995-06-07 2001-10-09 パーセプティブ バイオシステムズ，インコーポレーテッド Ｐｎａ−ｄｎａキメラと、このキメラ合成用のｐｎａシントン
JPH1025294A (ja) * 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
CA2249598A1 (en) * 1996-03-26 1997-10-02 Paul Joseph Gilligan Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
DE69734783T2 (de) * 1996-07-24 2006-08-17 Buchardt, Dorte Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2

Also Published As

Publication number Publication date
NZ329431A (en) 2000-01-28
CN1495184A (zh) 2004-05-12
JPH10182645A (ja) 1998-07-07
AU728865B2 (en) 2001-01-18
PL323969A1 (en) 1998-06-22
EP0853084A3 (de) 1998-09-09
CA2225366A1 (en) 1998-06-20
RU2228335C2 (ru) 2004-05-10
CN1193623A (zh) 1998-09-23
HU9702507D0 (en) 1998-03-02
CZ294437B6 (cs) 2005-01-12
NO975977D0 (no) 1997-12-19
AU4846697A (en) 1998-06-25
HK1012190A1 (en) 1999-07-30
CA2225366C (en) 2006-10-10
TW523515B (en) 2003-03-11
KR19980064655A (ko) 1998-10-07
IL122642A0 (en) 1998-08-16
DE59712958D1 (de) 2008-09-25
NO975977L (no) 1998-06-22
BR9706387A (pt) 2000-03-14
NO314583B1 (no) 2003-04-14
EP0853084A2 (de) 1998-07-15
TR199701647A3 (tr) 1998-07-21
JP4620190B2 (ja) 2011-01-26
HUP9702507A2 (hu) 1999-05-28
ID19254A (id) 1998-06-28
DE19653646A1 (de) 1998-06-25
CN1101816C (zh) 2003-02-19
CZ411497A3 (cs) 1998-07-15
EP0853084B1 (de) 2008-08-13
ATE404562T1 (de) 2008-08-15
TR199701647A2 (xx) 1998-07-21
MX9710277A (es) 1998-10-31
HUP9702507A3 (en) 1999-12-28
AR010700A1 (es) 2000-06-28

Similar Documents

Publication Publication Date Title
ZA9711317B (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them.
HK1018780A1 (en) 6-Phenylpyridine-2-ylamine derivatives, the composition and use thereof.
ZA979220B (en) New oxadiazoles, processes for their preparation and their use as pharmaceutical compositions.
HUP0000658A3 (en) Sulphonamide derivatives, process for their preparation, and their use as medicaments
HUP0001186A3 (en) Purine l-nucleosides,analogs and pharmaceutical compositions thereof
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
HUP9904051A3 (en) 4-hetaroylpyrazol derivatives, preparation and use thereof as herbicides
IL142372A0 (en) 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
ZA971659B (en) Erythromycin derivatives, their preparation process and their use as medicaments.
ZA9710187B (en) Substituted nitrogen heterocycles, processes for their preparation and their use as pesticides.
HUP9904104A3 (en) Derivates from piperidine-keto acid,their preparation and use
ZA985121B (en) 3-Substituted 3,4-dihyrothieno(2,3-d)pyrimidine derivatives their preparation and use.
GB9813725D0 (en) Depilatory compositions, methods for their preparation and their use
IL126624A0 (en) 3-descladinose-2, 3-anhydroerythromycin derivatives
ZA200109602B (en) Purine derivatives, preparation method and pharmaceutical compositions containing same.
ZA973883B (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents.
ZA9610460B (en) New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions.
ZA989664B (en) 3-substituted tetrahydropyrimidinone derivatives, their preparation and use.
ZA976329B (en) Substituted pyrazolylpyrazole derivatives, process for their preparation, and their use as herbicides.
EP0672736A3 (de) Beschichtungsmischungen, ein Verfahren zu ihrer Herstellung und ihre Verwendung.
ZA972894B (en) Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics.
ZA9810625B (en) Benzylidenepyrazolones, their preparation and use.
ZA989571B (en) 2-Substituted 1,2-Benzoisonthiazole derivatives, their preparation and use.
ZA966749B (en) Endoparasiticidal compositions based on didepsipeptides, new didepsipeptides and processes for their preparation.